Cell Signaling Technology (CST) is highlighting its LC-MS proteomics services, positioning the offering as a tool capable of supporting projects of virtually any scale, from small, targeted experiments to large, comprehensive proteome-wide studies. The company frames the service around a central message: no proteomics project is too large, or too small, to generate meaningful scientific insight.
A tool spanning the drug development lifecycle
According to CST, LC-MS proteomics can support researchers across several distinct but connected stages of drug development. This includes identifying and validating drug targets early in the discovery process, uncovering critical biomarkers for pharmacology groups working to characterize a compound’s effects, determining on- and off-target effects that shape a drug candidate’s safety and specificity profile, and understanding a compound’s mechanism of action as it moves through development.
This breadth reflects how central proteomics has become to modern drug discovery and development pipelines. Rather than serving a single narrow function, LC-MS-based proteomic analysis increasingly touches nearly every major decision point along the path from initial target identification to late-stage mechanistic characterization, making it a tool that discovery, pharmacology, and development teams alike may draw on at different points in a program’s lifecycle.
Two decades of proteomics discovery experience
CST notes that it has been an innovator in proteomics discovery for over 20 years, a history that includes its role as the inventor of PTMScan® Technology, a method widely used for enriching and identifying post-translationally modified peptides. This long-standing presence in the proteomics space underpins the company’s positioning as an experienced partner for projects that may require not just instrumentation, but also deep interpretive expertise in translating complex mass spectrometry data into actionable biological insight.
The company emphasizes that its experts oversee projects from initial planning through to final interpretation of results. This includes early-stage work such as determining sample requirements and experimental design, decisions that can significantly influence the quality and interpretability of proteomic data long before any samples reach the mass spectrometer. By maintaining involvement across the full arc of a project, from planning through data interpretation, CST positions its service as more than instrument access, but as an end-to-end scientific partnership.
Working with the Proteomics Analytical Team
Researchers are invited to partner with CST’s Proteomics Analytical Team to uncover on- and off-target effects across the entire proteome, using the company’s LC-MS infrastructure and expertise, including systems such as the Thermo Scientific Astral LC-MS platform referenced in the company’s promotional materials. This proteome-wide approach is particularly relevant for programs seeking to understand not just whether a compound engages its intended target, but how broadly its effects extend across the proteome, an increasingly important consideration for compounds such as molecular degraders, where off-target protein degradation can carry significant safety implications.
Service commitments for projects of any scale
CST outlines several specific commitments as part of its proteomics offering. The company states it guarantees on-time delivery for projects of any size, addressing a common concern for research teams operating under tight development timelines where delays in data delivery can cascade into broader program delays. It also emphasizes easy-to-interpret data packages, aimed at reducing the burden on research teams that may not have deep in-house bioinformatics or mass spectrometry expertise to independently parse complex proteomic datasets.
Additionally, CST highlights its high capacity to run large samples quickly, a capability relevant to research programs generating substantial sample volumes, whether from large screening campaigns, extensive time-course studies, or broad target validation efforts across multiple candidate compounds.
Relevance to targeted protein degradation and beyond
While the offering is framed broadly across drug discovery and development, the reference to exposing “degrader blind spots” points to a particular relevance for researchers working in targeted protein degradation, a rapidly growing area of drug development where compounds such as molecular glues and PROTACs are designed to selectively eliminate disease-relevant proteins. For this class of therapeutics, understanding the full scope of on- and off-target degradation across the proteome is especially critical, since unintended degradation of off-target proteins can carry meaningful safety and selectivity implications that may not surface through more conventional target-engagement assays alone.
By offering comprehensive, proteome-wide LC-MS analysis alongside guaranteed turnaround times and interpretive support, CST positions its proteomics services as a resource for research teams working across a range of modalities, from traditional small-molecule inhibitors to newer degrader technologies, seeking a clearer, more complete picture of how their compounds behave once they enter a biological system.
Researchers interested in learning more about CST’s proteomics offerings and how the Proteomics Analytical Team can support target validation, biomarker discovery, and mechanism-of-action studies can find additional details through the company’s website.